Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma

This study explores a novel therapeutic strategy for relapsed/refractory (R/R) Burkitt lymphoma (BL) by integrating autologous hematopoietic stem cell transplantation (ASCT) with tandem anti-CD19/CD22 chimeric antigen receptor (CAR) T cell therapy. A 20-year-old Asian male with refractory BL, whose...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2024-12, Vol.15
Main Authors: Xiaodan Luo, Ao Chen, Le Qin, Robert Weinkove, Rong Zhao, Ting Ye, Sihui Chen, Jianli Tang, Jianbo Liu, Jiayu Huang, Boyun Shi, Danyun Yuan, Huo Tan, Dajiang Qin, Zhaoyang Tang, Peng Li, Runhui Zheng
Format: Article
Language:English
Subjects:
autologous hematopoietic stem cell transplantation
CAR T-cell therapy
CD19/CD22 dual target
immunotherapy
relapsed/refractory Burkitt lymphoma
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study explores a novel therapeutic strategy for relapsed/refractory (R/R) Burkitt lymphoma (BL) by integrating autologous hematopoietic stem cell transplantation (ASCT) with tandem anti-CD19/CD22 chimeric antigen receptor (CAR) T cell therapy. A 20-year-old Asian male with refractory BL, whose lymphoma had not responded to multiple chemoimmunotherapy regimens, received myeloablative ASCT followed three days later by infusion of a novel third-generation CAR T cells engineered with CD28 and CD3ζ signaling domains, along with a TLR2 costimulatory domain. This resulted in sustained complete remission at the 306-day follow-up, without experiencing any severe complications. This case suggests that combining myeloablative ASCT with tandem anti-CD19/CD22 CAR T cell therapy could be an effective approach for R/R BL, warranting further clinical validation.
ISSN:1664-3224
DOI:10.3389/fimmu.2024.1497736